2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Devices, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Computer Vision, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Systems-Based Hematology, Value, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Embryo/Fetus, Pediatric, Pregnant, Young Adult
PAPER

1162 Smartphone app for noninvasive, at-home hemoglobin monitoring and correlation with vaso-occlusive crisis in pediatric sickle cell disease patients.

Robert G Mannino, PhD, Kunjan Rana, PhD2, Wilbur A. Lam, MD, PhD3, Inga Hegemann, MD4, Janne Toftegaard Madsen5, Erika Tyburski6
1 Sanguina, Inc., Atlanta, Georgia, United States
2 Novo Nordisk, Copenhagen, Denmark
3 Sanguina, Inc., Atlanta, Georgia, United States
4 Novo Nordisk, Zurich, Switzerland
5 Novo Nordisk, Zurich, Switzerland
6 Sanguina, Inc., Atlanta, Georgia, United States

Anemia is the world’s most common blood condition, impacting more than 2 billion people globally.  Monitoring anemia is especially important in sickle cell disease (SCD), where anemia severity is associated with complications, end organ damage, and poor quality of life for the more than 100k individuals in the USA alone. This is particularly important in pediatric SCD populations, where anemia is a hallmark symptom due to hemolysis, acute splenic sequestration, and acute marrow aplasia (Parvo B19) and may necessitate emergency intervention including blood transfusions. The gold standard test for hemoglobin (Hgb) monitoring is the complete blood count (CBC), which is invasive and costly. Therefore, we developed a noninvasive, easy to use, and accessible smartphone app that measures Hgb levels using fingernail pictures. Our work presented here investigated the usability and performance of measuring Hgb in pediatric patients with SCD. Of interest is to profile and potentially predict vaso-occlusive crisis (VOC), the hallmark symptom of SCD causing fatigue, pain, and hospitalization, of which no predictive biomarkers have been accepted in clinical practice. Therefore, we investigated the app Hgb signal leading up to a crisis. This investigational app has not been reviewed or approved for SCD by the FDA.

In this study, we enrolled 60 participants (26 Female/34 Male, ages 6 months to 5 years: 15, ages 6 years to 11 years: 23, ages 12 years to 17 years: 22) diagnosed with SCD (40 Hgb SS, 15 Hgb SC, 3 Hgb Sb+ thalassemia, and 2 with an unknown genotype) in 2 cities (Atlanta, Washington D.C.), of which 4 subjects were excluded from analysis due to protocol violations. The study consisted of up to 3 site visits across a total of 12 weeks. At each visit, participants took an app test and received a CBC. This initial CBC was used for calibration, and while not required for app functionality, follow up visits were used to recalibrate the app in order to maximize use of available data. In between visits, participants took app tests every other day and recorded their symptoms, in particular, VOC-associated symptoms (e.g. pain level, extremity pain, fatigue, headache, etc.), and medications in the app.

 Here we report the mean absolute error (MAE) of the app Hgb measurements to be ±0.87 g/dL (R = 0.86) which is similar to what we reported in adult populations with and without SCD (Mannino et. al., Nature Communications, 2018, Mannino et. al. ASH 2024, Mannino et. al. PNAS, 2025). Furthermore, upon analyzing patient reported VOC events in the app along with app-reported Hgb levels in the 5 days leading up to a VOC, we noticed that Hgb levels were more variable when compared to 5-day windows in which no VOC was reported (mean absolute day-to-day app Hgb difference in the 5-day window: preceding VOC, 0.2 g/dL; no VOC, 0.1 g/dL, p<0.0005). In fact, Hgb levels varied by as much as 1 g/dL in the lead up to a VOC compared to VOC-free windows which is in line with previous findings in adults.

Furthermore, study participants and their caregivers found the app to be highly usable. 100% of study participants and their caregivers stated that “the app was easy to use”, and 96% of the caregivers reported that they would be willing incorporate the app into their child’s daily routines. This result was supported by the fact that study participants and their caregivers continued to use the app after the study was complete, when 25 individual study participants took a total of 164 tests in the 6 months after compensation and contact were ended but app access was retained. Moreover, the noninvasive nature of this tool is cited by participants as a major positive attribute, as many children are apprehensive about the more invasive traditional tests for measuring Hgb.

The ability of the app to accurately measure Hgb levels in children as well as robust at-home compliance highlights the utility of this tool as an accessible noninvasive monitoring platform. Furthermore, the distinct signal characterized by fluctuating app readings before a VOC could be used as the basis for a VOC prediction model, allowing people with SCD to take prophylactic measures designed to mitigate the severity and duration of the upcoming VOC. Overall, results suggest that the noninvasive app is a useful tool for children suffering from SCD and their caregivers to frequently monitor their Hgb levels, empowering better management of their condition, particularly as it relates to VOCs.

Robert G Mannino, PhD: Sanguina, Inc. - Current equity holder in private company; Novo Nordisk - Research Funding; Sanguina, Inc. - Research Funding; Sanguina, Inc. - Patents & Royalties; Sanguina, Inc. - Current Employment